PMC:7228307 / 61606-62087 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1246","span":{"begin":164,"end":168},"obj":"Gene"},{"id":"1247","span":{"begin":348,"end":352},"obj":"Gene"}],"attributes":[{"id":"A1246","pred":"tao:has_database_id","subj":"1246","obj":"Gene:2213"},{"id":"A1247","pred":"tao:has_database_id","subj":"1247","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T458","span":{"begin":263,"end":276},"obj":"Body_part"},{"id":"T459","span":{"begin":362,"end":370},"obj":"Body_part"}],"attributes":[{"id":"A458","pred":"fma_id","subj":"T458","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A459","pred":"fma_id","subj":"T459","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T32","span":{"begin":263,"end":276},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"uberon_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T998","span":{"begin":24,"end":26},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T999","span":{"begin":164,"end":166},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T1000","span":{"begin":263,"end":276},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T1001","span":{"begin":348,"end":350},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T75881","span":{"begin":228,"end":236},"obj":"Chemical"}],"attributes":[{"id":"A86945","pred":"chebi_id","subj":"T75881","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T266","span":{"begin":472,"end":480},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T644","span":{"begin":0,"end":6},"obj":"RB"},{"id":"T645","span":{"begin":7,"end":11},"obj":"IN"},{"id":"T646","span":{"begin":12,"end":15},"obj":"CD"},{"id":"T647","span":{"begin":16,"end":20},"obj":"NN"},{"id":"T648","span":{"begin":21,"end":23},"obj":"IN"},{"id":"T649","span":{"begin":24,"end":26},"obj":"NN"},{"id":"T650","span":{"begin":27,"end":29},"obj":"TO"},{"id":"T651","span":{"begin":30,"end":37},"obj":"VB"},{"id":"T652","span":{"begin":38,"end":41},"obj":"DT"},{"id":"T653","span":{"begin":41,"end":42},"obj":"-COMMA-"},{"id":"T654","span":{"begin":43,"end":46},"obj":"DT"},{"id":"T655","span":{"begin":47,"end":55},"obj":"JJ"},{"id":"T656","span":{"begin":56,"end":59},"obj":"NN"},{"id":"T657","span":{"begin":60,"end":62},"obj":"IN"},{"id":"T658","span":{"begin":63,"end":76},"obj":"RB"},{"id":"T659","span":{"begin":77,"end":85},"obj":"VBN"},{"id":"T660","span":{"begin":86,"end":90},"obj":"NNS"},{"id":"T661","span":{"begin":91,"end":96},"obj":"WP-DOLLAR-"},{"id":"T662","span":{"begin":97,"end":107},"obj":"JJ"},{"id":"T663","span":{"begin":108,"end":118},"obj":"NNS"},{"id":"T664","span":{"begin":119,"end":122},"obj":"VBP"},{"id":"T665","span":{"begin":123,"end":131},"obj":"VBN"},{"id":"T666","span":{"begin":132,"end":135},"obj":"IN"},{"id":"T667","span":{"begin":136,"end":139},"obj":"DT"},{"id":"T668","span":{"begin":140,"end":150},"obj":"NN"},{"id":"T669","span":{"begin":151,"end":153},"obj":"IN"},{"id":"T670","span":{"begin":154,"end":163},"obj":"JJ"},{"id":"T671","span":{"begin":164,"end":168},"obj":"NN"},{"id":"T672","span":{"begin":169,"end":176},"obj":"NNS"},{"id":"T673","span":{"begin":177,"end":180},"obj":"MD"},{"id":"T674","span":{"begin":181,"end":188},"obj":"VB"},{"id":"T675","span":{"begin":189,"end":197},"obj":"JJ"},{"id":"T676","span":{"begin":198,"end":208},"obj":"NNS"},{"id":"T677","span":{"begin":209,"end":211},"obj":"IN"},{"id":"T678","span":{"begin":212,"end":215},"obj":"DT"},{"id":"T679","span":{"begin":216,"end":224},"obj":"NN"},{"id":"T680","span":{"begin":225,"end":227},"obj":"IN"},{"id":"T681","span":{"begin":228,"end":236},"obj":"NN"},{"id":"T682","span":{"begin":237,"end":246},"obj":"NNS"},{"id":"T683","span":{"begin":247,"end":249},"obj":"IN"},{"id":"T684","span":{"begin":250,"end":255},"obj":"NN"},{"id":"T685","span":{"begin":256,"end":258},"obj":"IN"},{"id":"T686","span":{"begin":259,"end":262},"obj":"DT"},{"id":"T687","span":{"begin":263,"end":269},"obj":"JJ"},{"id":"T688","span":{"begin":270,"end":276},"obj":"NN"},{"id":"T689","span":{"begin":278,"end":282},"obj":"JJ"},{"id":"T690","span":{"begin":283,"end":293},"obj":"NN"},{"id":"T691","span":{"begin":294,"end":303},"obj":"NNS"},{"id":"T692","span":{"begin":304,"end":308},"obj":"MD"},{"id":"T693","span":{"begin":309,"end":314},"obj":"VB"},{"id":"T694","span":{"begin":315,"end":317},"obj":"TO"},{"id":"T695","span":{"begin":318,"end":325},"obj":"VB"},{"id":"T696","span":{"begin":326,"end":329},"obj":"DT"},{"id":"T697","span":{"begin":330,"end":334},"obj":"JJ"},{"id":"T698","span":{"begin":335,"end":344},"obj":"NN"},{"id":"T699","span":{"begin":345,"end":347},"obj":"IN"},{"id":"T700","span":{"begin":348,"end":361},"obj":"JJ"},{"id":"T701","span":{"begin":362,"end":370},"obj":"NN"},{"id":"T702","span":{"begin":371,"end":377},"obj":"JJ"},{"id":"T703","span":{"begin":378,"end":390},"obj":"NNS"},{"id":"T704","span":{"begin":391,"end":394},"obj":"CC"},{"id":"T705","span":{"begin":395,"end":400},"obj":"VB"},{"id":"T706","span":{"begin":401,"end":417},"obj":"JJ"},{"id":"T707","span":{"begin":418,"end":424},"obj":"NN"},{"id":"T708","span":{"begin":425,"end":428},"obj":"IN"},{"id":"T709","span":{"begin":429,"end":432},"obj":"DT"},{"id":"T710","span":{"begin":433,"end":442},"obj":"NN"},{"id":"T711","span":{"begin":443,"end":445},"obj":"IN"},{"id":"T712","span":{"begin":446,"end":457},"obj":"JJ"},{"id":"T713","span":{"begin":458,"end":461},"obj":"CC"},{"id":"T714","span":{"begin":462,"end":471},"obj":"JJ"},{"id":"T715","span":{"begin":472,"end":480},"obj":"NNS"}],"relations":[{"id":"R703","pred":"arg2Of","subj":"T688","obj":"T685"},{"id":"R704","pred":"arg1Of","subj":"T688","obj":"T686"},{"id":"R705","pred":"arg1Of","subj":"T688","obj":"T687"},{"id":"R706","pred":"arg1Of","subj":"T691","obj":"T689"},{"id":"R707","pred":"arg1Of","subj":"T691","obj":"T690"},{"id":"R708","pred":"arg1Of","subj":"T691","obj":"T692"},{"id":"R709","pred":"arg2Of","subj":"T693","obj":"T692"},{"id":"R660","pred":"arg1Of","subj":"T674","obj":"T644"},{"id":"R661","pred":"arg1Of","subj":"T644","obj":"T645"},{"id":"R662","pred":"arg2Of","subj":"T647","obj":"T645"},{"id":"R663","pred":"arg1Of","subj":"T647","obj":"T646"},{"id":"R664","pred":"arg1Of","subj":"T647","obj":"T648"},{"id":"R665","pred":"arg2Of","subj":"T649","obj":"T648"},{"id":"R666","pred":"arg1Of","subj":"T651","obj":"T650"},{"id":"R667","pred":"modOf","subj":"T647","obj":"T650"},{"id":"R668","pred":"arg2Of","subj":"T652","obj":"T651"},{"id":"R669","pred":"arg1Of","subj":"T674","obj":"T653"},{"id":"R670","pred":"arg1Of","subj":"T656","obj":"T654"},{"id":"R671","pred":"arg1Of","subj":"T656","obj":"T655"},{"id":"R672","pred":"arg1Of","subj":"T656","obj":"T657"},{"id":"R673","pred":"arg2Of","subj":"T660","obj":"T657"},{"id":"R674","pred":"arg1Of","subj":"T659","obj":"T658"},{"id":"R675","pred":"arg1Of","subj":"T660","obj":"T659"},{"id":"R676","pred":"arg1Of","subj":"T663","obj":"T661"},{"id":"R677","pred":"arg2Of","subj":"T660","obj":"T661"},{"id":"R678","pred":"arg1Of","subj":"T663","obj":"T662"},{"id":"R679","pred":"arg1Of","subj":"T663","obj":"T664"},{"id":"R680","pred":"arg2Of","subj":"T665","obj":"T664"},{"id":"R681","pred":"arg2Of","subj":"T663","obj":"T665"},{"id":"R682","pred":"arg1Of","subj":"T665","obj":"T666"},{"id":"R683","pred":"arg2Of","subj":"T668","obj":"T666"},{"id":"R684","pred":"arg1Of","subj":"T668","obj":"T667"},{"id":"R685","pred":"arg1Of","subj":"T668","obj":"T669"},{"id":"R686","pred":"arg2Of","subj":"T672","obj":"T669"},{"id":"R687","pred":"arg1Of","subj":"T672","obj":"T670"},{"id":"R688","pred":"arg1Of","subj":"T672","obj":"T671"},{"id":"R689","pred":"arg1Of","subj":"T656","obj":"T673"},{"id":"R690","pred":"arg2Of","subj":"T674","obj":"T673"},{"id":"R691","pred":"arg1Of","subj":"T656","obj":"T674"},{"id":"R692","pred":"arg2Of","subj":"T676","obj":"T674"},{"id":"R693","pred":"arg1Of","subj":"T676","obj":"T675"},{"id":"R694","pred":"arg1Of","subj":"T676","obj":"T677"},{"id":"R695","pred":"arg2Of","subj":"T679","obj":"T677"},{"id":"R696","pred":"arg1Of","subj":"T679","obj":"T678"},{"id":"R697","pred":"arg1Of","subj":"T679","obj":"T680"},{"id":"R698","pred":"arg2Of","subj":"T682","obj":"T680"},{"id":"R699","pred":"arg1Of","subj":"T682","obj":"T681"},{"id":"R700","pred":"arg1Of","subj":"T679","obj":"T683"},{"id":"R701","pred":"arg2Of","subj":"T684","obj":"T683"},{"id":"R702","pred":"arg1Of","subj":"T674","obj":"T685"},{"id":"R710","pred":"arg1Of","subj":"T691","obj":"T693"},{"id":"R711","pred":"arg2Of","subj":"T704","obj":"T693"},{"id":"R712","pred":"arg1Of","subj":"T704","obj":"T694"},{"id":"R713","pred":"arg1Of","subj":"T691","obj":"T695"},{"id":"R714","pred":"arg2Of","subj":"T698","obj":"T695"},{"id":"R715","pred":"arg1Of","subj":"T698","obj":"T696"},{"id":"R716","pred":"arg1Of","subj":"T698","obj":"T697"},{"id":"R717","pred":"arg1Of","subj":"T698","obj":"T699"},{"id":"R718","pred":"arg2Of","subj":"T703","obj":"T699"},{"id":"R719","pred":"arg1Of","subj":"T703","obj":"T700"},{"id":"R720","pred":"arg1Of","subj":"T703","obj":"T701"},{"id":"R721","pred":"arg1Of","subj":"T703","obj":"T702"},{"id":"R722","pred":"arg1Of","subj":"T695","obj":"T704"},{"id":"R723","pred":"arg2Of","subj":"T705","obj":"T704"},{"id":"R724","pred":"arg1Of","subj":"T691","obj":"T705"},{"id":"R725","pred":"arg2Of","subj":"T707","obj":"T705"},{"id":"R726","pred":"arg1Of","subj":"T707","obj":"T706"},{"id":"R727","pred":"arg1Of","subj":"T705","obj":"T708"},{"id":"R728","pred":"arg2Of","subj":"T710","obj":"T708"},{"id":"R729","pred":"arg1Of","subj":"T710","obj":"T709"},{"id":"R730","pred":"arg1Of","subj":"T710","obj":"T711"},{"id":"R731","pred":"arg2Of","subj":"T715","obj":"T711"},{"id":"R732","pred":"arg1Of","subj":"T715","obj":"T712"},{"id":"R733","pred":"arg1Of","subj":"T712","obj":"T713"},{"id":"R734","pred":"arg2Of","subj":"T714","obj":"T713"},{"id":"R735","pred":"arg1Of","subj":"T715","obj":"T714"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1246","span":{"begin":164,"end":168},"obj":"Gene"},{"id":"1247","span":{"begin":348,"end":352},"obj":"Gene"}],"attributes":[{"id":"A1247","pred":"pubann:denotes","subj":"1247","obj":"Gene:2213"},{"id":"A1246","pred":"pubann:denotes","subj":"1246","obj":"Gene:2213"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T340","span":{"begin":0,"end":277},"obj":"Sentence"},{"id":"T341","span":{"begin":278,"end":481},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T29","span":{"begin":263,"end":276},"obj":"Body_part"}],"attributes":[{"id":"A29","pred":"uberon_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T827","span":{"begin":330,"end":334},"obj":"Protein"}],"attributes":[{"id":"A827","pred":"uniprot_id","subj":"T827","obj":"https://www.uniprot.org/uniprot/Q8N1N2"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T457","span":{"begin":263,"end":276},"obj":"Body_part"},{"id":"T458","span":{"begin":362,"end":370},"obj":"Body_part"}],"attributes":[{"id":"A458","pred":"fma_id","subj":"T458","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A457","pred":"fma_id","subj":"T457","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}

{"project":"LitCovid-sentences","denotations":[{"id":"T340","span":{"begin":0,"end":277},"obj":"Sentence"},{"id":"T341","span":{"begin":278,"end":481},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases."}